We have both prevention and symptomatic trials. Our current prevention trial is listed at the top, followed by our symptomatic trials.
The purpose of the EARLY Trial is to evaluate the safety and efficacy of an investigational medication (a "BACE" inhibitor, which stops the formation of the building blocks of amyloid in the brain) in people at risk of developing Alzheimer’s disease dementia.
The primary objective of the study is to evaluate the efficacy of monthly doses of aducanumab in slowing cognitive and functional impairment as compared with placebo in participants with early AD.
The Aware Study assesses the effectiveness and safety of an investigational medication (monoclonal antibody - passive vaccine - that removes abnormal tau protein from the brain) to determine whether it can reduce symptoms in early Alzheimer's disease (AD).